Skip to content

Main Navigation

Fennec Pharmaceuticals
Fennec Pharmaceuticals
  • For Families
    • Advocacy Groups
    • Family Stories
    • Named Patient Access
  • Product
  • Science
    • Cisplatin-Induced Hearing Loss
  • About Us
    • Our Mission
    • Our Team
  • Investors
    • Corporate Profile
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
  • Contact Us
  • For Families
    • Advocacy Groups
    • Family Stories
    • Named Patient Access
  • Product
  • Science
    • Cisplatin-Induced Hearing Loss
  • About Us
    • Our Mission
    • Our Team
  • Investors
    • Corporate Profile
    • Stock Information
    • News & Events
    • Financial Information
    • Corporate Governance
  • Contact Us

Helping kids hear the future

Fennec Pharmaceuticals is a biotechnology company dedicated to improving the lives of children with cancer who experience hearing loss as a result of chemotherapy.

Discover what we stand for
Explore what we’re focused on
See product details

Latest News

  • 2023-05-11T06:01:00Fennec Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update
  • 2023-05-08T06:15:00Fennec Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023
  • 2023-03-31T08:03:00Fennec Pharmaceuticals Receives Positive CHMP Opinion for Pedmarqsi™ (sodium thiosulfate) to Reduce the Risk of Hearing Loss in Pediatric Oncology Patients
See More

Resources

For Investors
For Families

You are now leaving Fennec Pharmaceuticals to access a product-specific website.

Please visit us again soon!

Continue

Fennec® is a registered trademark of Fennec Pharmaceuticals Inc.
©2022 Fennec Pharmaceuticals Inc. All rights reserved. FEN-1538-v1 04/23

  • Privacy Policy
  • Cookie Policy
  • Terms & Conditions
  • Careers
  • Sitemap